Click Here to return To Results

 

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis NEJM 362:387-401, 456, Kappos, L.,et al, 2010 See this aricle in Pubmed Article Abstract As compared with placebo, both doses of oral fingolimod improved the relapse rate, the risk of disability progression, and end points on MRI. These benefits will need to be weighed against possible long-term risks.

Related Tags

(click to filter results - removes previous filter) adverse drug reaction bradycardia complications conduction block disability,neurological efficacy fingolimod liver function enzymes MRI MRI,abnormal multiple sclerosis multiple sclerosis,relapsing multiple sclerosis,treatment of safety treatment of neurologic disorder

Click Here to return To Results